group
presum
druglik
molecul
possess
high
silico
affin
angiotensinconvert
enzym
comput
design
enzym
promis
new
target
cardioren
diseas
coronaviru
infect
set
substrat
analog
molecul
optim
mean
leapfrog
modul
sybyl
packag
later
molinspir
molsoft
use
screen
compound
low
oral
bioavail
similarli
osiri
use
screen
compound
seriou
side
effect
end
sever
stage
screen
seven
candid
antivir
drug
fulfil
evalu
criteria
obtain
amen
futur
studi
vitro
vivo
design
ligand
final
evalu
quantit
structur
activ
relationship
studi
molecul
use
carri
qsar
model
fom
four
molecul
taken
extern
set
yield
model
q
r
valu
structur
correspond
xray
crystallographi
extracellular
metallopeptidas
domain
complex
ligand
extract
brook
pdb
inhibitor
develop
dale
et
al
sketch
energet
minim
charg
sybyl
packag
version
addit
optim
structur
compound
prepar
run
dock
experi
follow
procedur
flexx
program
use
search
algorithm
find
bind
pose
ligand
respect
structur
enzym
obtain
rcsb
protein
data
bank
definit
activ
site
dock
simul
radiu
taken
subsequ
one
pose
select
rank
rank
consensu
among
score
function
g
score
pmf
score
score
chemscor
dock
protocol
implement
studi
quantit
structur
activ
monocarboxypeptidas
angiotensinconvert
enzym
novel
biochem
compon
reninangiotensin
system
whose
discoveri
ad
layer
complex
classic
concept
cardiovascular
regulatori
system
hitherto
physiolog
patholog
role
fulli
deciph
report
implic
cardiovascular
renal
biolog
obes
inflammatori
activ
diabet
enzym
also
establish
function
receptor
scv
etiolog
agent
sever
acut
respiratori
syndrom
hcov
viru
herebi
consid
import
target
control
diseas
develop
antiscv
therapeut
agent
paramount
import
due
high
lethal
scv
infect
enorm
econom
social
impact
fear
renew
outbreak
well
potenti
misus
virus
biolog
weapon
besid
known
divers
coronavirus
bind
similar
region
impli
ligand
could
inhibit
infect
scv
although
viru
circul
human
popul
modestli
pathogen
case
inhibitor
would
use
treatment
subset
seriou
case
pathogen
form
viru
work
comput
method
appli
obtain
inhibitor
viral
fusion
event
previous
proven
abil
target
relationship
qsar
set
compound
figur
tabl
taken
public
dale
et
al
util
comsia
compar
molecular
similar
analysi
analys
model
develop
sybyl
packag
use
ligand
tabl
top
rank
pose
dock
flexx
align
ligand
perform
comsia
descriptor
steric
electrostat
hydrophob
hydrogen
bond
donor
hydrogen
bond
acceptor
calcul
standard
tripo
forc
field
everi
point
three
dimension
lattic
use
sp
carbon
probe
charg
standard
comsia
cutoff
valu
method
partial
least
squar
pl
implement
qsar
modul
sybyl
use
construct
valid
model
column
filter
set
kcalmol
speed
analysi
reduc
nois
comsia
descriptor
serv
independ
variabl
pic
valu
depend
variabl
pl
regress
analysi
perform
deriv
model
calcul
use
leav
one
loo
crossvalid
method
optimum
number
compon
nc
use
deriv
non
crossvalid
model
defin
number
compon
lead
highest
r
crossvalid
q
lowest
standard
error
predict
sep
obtain
statist
confid
limit
analys
bootstrap
carri
group
optim
carri
leapfrog
lf
lf
secondgener
lead
optim
tool
design
seri
potenti
activ
ligand
molecul
bind
energi
calcul
lf
perform
three
major
compon
direct
steric
electrostat
implicit
hydrogen
bond
enthalpi
ligandcav
bind
use
tripo
forc
field
lf
ligand
atom
coordin
bin
increas
speed
bind
energi
ligand
atom
calcul
though
atom
actual
locat
center
cube
contain
atom
simpl
linear
express
yield
energi
interact
site
particular
ligand
atom
sum
ligand
atom
yield
overal
siteligand
interact
energi
lf
program
execut
bin
creat
contain
closest
residu
cocrystal
ligand
caviti
use
gener
sitepoint
charg
sitepoint
atom
posit
neg
lipophil
option
caviti
desolv
energi
use
inhibitor
tabl
ten
thousand
modif
stochast
perform
silico
admet
taken
increasingli
signific
place
within
drug
develop
pipelin
structur
optim
process
lf
give
rise
profus
chemic
structur
high
ligand
effici
assess
real
pharmaceut
use
success
filter
mean
onlin
servic
implement
depict
figur
set
qsarbas
propos
candid
underw
screen
well
employ
tool
predict
druglik
molinspir
http
www
molinspirationcomcgibinproperti
osiri
molsoft
http
wwwmolsoftcommprop
druglik
may
defin
complex
balanc
variou
molecular
properti
structur
featur
determin
whether
particular
molecul
similar
known
drug
wide
use
filter
druglik
properti
known
lipinski
rule
rule
five
origin
deal
oral
activ
compound
defin
four
simpl
physicochem
paramet
rang
mwt
log
p
hbond
donor
hbond
acceptor
associ
oral
activ
drug
achiev
phase
ii
clinic
statu
hand
toxic
respons
mani
compound
fail
reach
market
withdraw
signific
number
compound
market
approv
definit
activ
site
focus
comput
resourc
hydrophob
core
enzym
deepli
recess
shield
activ
site
common
structur
featur
proteas
serv
avoid
proteolysi
larg
structur
peptid
blind
dock
perform
ehit
scan
entir
protein
rigor
confirm
bind
site
ligand
protein
effect
one
select
dock
flexx
insid
specif
recognit
site
peptid
bond
cleav
found
three
pocket
display
render
connolli
surfac
figur
hydrophob
subsit
compos
residu
n
w
h
h
e
fig
show
pseudoleu
isobutyl
chain
inhibitor
tabl
pack
nice
big
enough
accommod
longer
chain
contrast
electrostat
chemic
environ
subsit
favour
interact
polar
residu
natur
substrat
thin
pocket
one
mayor
determin
substrat
specif
fact
topolog
differ
homologu
ace
exhibit
invers
mode
bind
lodg
benzyl
moieti
insid
subsit
wherea
inhibitor
bind
way
whole
structur
inhibitor
exclud
subcav
gener
larg
databas
mean
lf
program
optim
ligand
dock
target
lf
simul
structur
retain
place
insid
caviti
automat
optim
proceed
difficult
calcul
ligand
produc
lf
molecul
altogeth
accept
structur
obtain
databas
structur
highest
lf
affin
score
select
although
atom
start
strutur
protect
modif
imidazol
ring
amino
dicarboxyl
core
conserv
except
case
two
first
molecul
tabl
bind
mode
one
lf
gener
structur
activ
site
display
figur
share
two
carboxyl
group
compound
tabl
group
coordin
zn
linker
group
methylen
instead
amino
group
addit
chain
enlarg
posses
two
flurid
atom
ceto
group
establish
electrostat
interact
residu
n
e
final
ligand
e
oxygen
atom
connect
imidazol
ring
ethylpyridazin
moieti
parcial
occupi
subsit
pyridazin
ring
found
within
structur
sever
pharmaceut
drug
nitrogen
atom
contain
heterocycl
compound
pyridazin
pyridazinon
phthalazin
import
structur
featur
mani
biolog
activ
compound
show
divers
pharmacolog
properti
overal
lfgener
scaffold
fit
high
complementar
catalyt
site
addit
comsia
qsar
model
built
dockedbas
align
method
led
sever
signif
comsia
model
contrast
comfa
model
one
elabor
alig
sybyl
modul
select
best
comsia
model
possibl
combin
physicochem
standard
properti
tri
respect
statist
model
q
valu
summar
tabl
best
comsia
model
dale
ligand
yield
q
r
valu
best
comsia
model
ligand
tabl
yield
q
r
valu
steric
paramet
alon
gave
best
statist
case
steric
contribut
contour
map
comsia
plot
figur
show
greater
potenc
ligand
also
name
respect
ligand
relat
overlap
ligand
moieti
green
field
fact
benzen
ring
ligand
farer
yellow
polyhedr
ligand
chlorid
atom
ring
ligand
goe
green
region
addit
imidazol
ring
ligand
chang
orient
atom
much
separ
unfavour
yellow
region
steric
field
biolog
activ
lfgener
chemotyp
calcul
comsia
model
result
shown
tabl
suggest
potent
previous
report
inhibitor
file
gener
lf
convert
smile
format
cactu
translat
http
cactusncinihgov
servicestransl
next
these
molecul
submit
onlin
server
molinspir
predict
import
molecular
properti
logp
polar
surfac
area
number
hydrogen
bond
donor
acceptor
molecular
weight
number
oxygen
nitrogen
atom
number
hydrogen
attach
n
number
violat
number
rotabl
bond
volum
screen
top
lf
compound
gener
structur
optim
hit
lipinski
rule
observ
predict
toxic
synthesi
compound
ensur
remov
compound
potenti
toxic
effect
number
silico
system
toxic
predict
avail
help
classif
toxic
nontox
compound
assess
studi
molecul
perform
mean
osiri
properti
explor
yield
select
prototyp
sinc
member
precomput
set
structur
fragment
characterist
harm
compound
encount
screen
structur
claim
free
toxic
effect
trade
drug
therefor
indic
neither
risk
mutagen
tumorigen
irrit
reproduct
effect
posit
control
use
ritonavir
ribavirin
amantadin
acyclovir
fragment
submit
molecul
gave
rise
toxic
alert
shown
tabl
accord
osiri
potent
compound
tabl
cocrystal
ligand
turn
also
mutagen
virtu
benzen
ring
moieti
bear
two
chlorid
meta
posit
nonetheless
compound
contain
halogen
pyridin
ring
pass
osiri
test
addit
molinspir
server
use
predict
bioactiv
four
import
drug
target
gpcr
ligand
kinas
inhibitor
ion
channel
modul
nuclear
receptor
method
implement
molinspir
use
sophist
bayesian
statist
compar
structur
repres
ligand
activ
particular
target
structur
inact
molecul
identifi
substructur
featur
typic
activ
molecul
descrip
tor
calcul
eight
previous
screen
entiti
regist
tabl
posit
control
includ
drug
propanolol
xylocain
imatinib
estradiol
conspicu
drug
target
mention
class
receptor
celullar
toxic
observ
molecul
ligand
shown
tabl
molsoft
calcul
paramet
molecular
weight
hydrogen
bond
acceptor
donor
logp
log
psa
molecular
volum
number
estereogen
center
regist
tabl
figur
sinc
member
precomput
set
structur
fragment
characterist
harm
compound
encount
screen
structur
claim
free
toxic
effect
trade
drug
therefor
indic
would
risk
mutagen
tumorigen
irrit
reproduct
effect
besid
accord
model
predict
lfdesign
molecul
potent
start
compound
develop
could
activ
nanomolar
rang
previous
studi
achiev
increas
potenc
bioactiv
molecul
summari
seven
therapeut
entiti
high
calcul
druglik
propos
synthes
experiment
evalu
obsticl
regard
chemotyp
b
c
sever
chiral
center
impli
rather
difficult
synthes
though
precis
admet
predict
method
limit
possibl
molecul
tabl
pass
filter
turn
safe
effect
drug
